Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Fullmektig i EP:
2013.01.15, US 201361752799 P
BENTEYN DAPHNE ET AL: "Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 2, November 2013 (2013-11), page Article No.: e134, ISSN: 2162-2531(print) (B1)
WO-A2-2007/120673 (B1)
DAO TAO ET AL: "An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.", ONCOIMMUNOLOGY 2017, vol. 6, no. 2, 2017, page e1252895, ISSN: 2162-4011 (B1)
DOUBROVINA EKATERINA ET AL: "Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.", BLOOD 23 AUG 2012, vol. 120, no. 8, 23 August 2012 (2012-08-23), pages 1633-1646, XP002759140, ISSN: 1528-0020 (B1)
EP-A1- 1 961 761 (B1)
EP-A1- 2 228 072 (B1)
EP-A2- 2 338 509 (B1)
OTTTENSMEIER ET AL.: "Wilm's tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electoporation : a Phase II non-randomised clinical trial (WIN)", EFFICACY AND MECHANISM EVALUATION, vol. 3, no. 3, April 2016 (2016-04), (B1)
PINILLA-IBARZ JAVIER ET AL: "Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.", HAEMATOLOGICA OCT 2005, vol. 90, no. 10, October 2005 (2005-10), pages 1324-1332, ISSN: 1592-8721 (B1)
T. Osada ET AL: "Induction of Wilms' Tumor Protein (WT1)-Specific Antitumor Immunity Using a Truncated WT1-Expressing Adenovirus Vaccine", Clinical Cancer Research, vol. 15, no. 8, 1 April 2009 (2009-04-01), pages 2789-2796, XP055079390, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-2589 (B1)
US-A1- 2006 084 609 (B1)
US-A1- 2007 082 860 (B1)
US-A1- 2012 301 492 (B1)
VAN TENDELOO VIGGO F ET AL: "Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, no. 31, August 2010 (2010-08), pages 13824-13829, ISSN: 0027-8424 (B1)
CHAISE CORALIE ET AL: "DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.", BLOOD 01 OCT 2008, vol. 112, no. 7, 1 October 2008 (2008-10-01), pages 2956-2964, ISSN: 1528-0020 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP2945647)
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP2945647)
|
Innkommende
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 12. avg. år (EP) | 2025.01.09 | 5010 | CPA GLOBAL LIMITED | Betalt og godkjent |
Forsinkelsesavgift patent | 2024.02.22 | 700 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 11. avg. år (EP) | 2024.02.22 | 3500 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 10. avg. år (EP) | 2023.01.10 | 3200 | CPA GLOBAL LIMITED | Betalt og godkjent |
Forsinkelsesavgift patent | 2022.02.08 | 700 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 9. avg. år (EP) | 2022.02.08 | 2850 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 8. avg. år (EP) | 2021.01.20 | 2550 | PAVIS PAYMENTS GMBH | Betalt og godkjent |
32019100 expand_more expand_less | 2020.12.14 | 5500 | Novagraaf Brevets | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|